Nosek, K., Leppert, W., Nosek, H., Wordliczek, J. and Onichimowski, D. (2017) A Comparison of Oral Controlled-Release Morphine and Oxycodone with Transdermal Formulations of Buprenorphine and Fentanyl in the Treatment of Severe Pain in Cancer Patients. Drug Design, Development and Therapy, 11, 2409-2419.
https://doi.org/10.2147/DDDT.S141007

has been cited by the following article:

• TITLE: Application of Ultrahigh Doses of Morphine in Systemic Multiple Epithelioid Hemangioendothelioma without Addiction: A Case Report

  AUTHORS: Minqiang Liu, Mingfei Ma, Xinzhong Ning, Renliang He

  KEYWORDS: Epithelioid Hemangioendothelioma, Morphine, Pain, Addiction

  JOURNAL NAME: Case Reports in Clinical Medicine, Vol.8 No.11, November 11, 2019

  ABSTRACT: Morphine is a potent opioid which is commonly used for relieving cancer pain with strong analgesic properties. Epithelioid hemangioendothelioma (EHE), a rare vascular tumor that can cause severe chronic pain, is usually diagnosed in a surgical biopsy. We describe ultrahigh doses of morphine used in a case of a 17-year-old male who suffered from severe chest pain with systemic multiple EHE. The total dosage of morphine was as high as 92,530 mg given within 164 days. However, we observed no indications that the patient was addicted.